Navigation Links
invivodata Captures Symptom Relief Data in Endometriosis Trial
Date:9/25/2008

Neurocrine Biosciences Demonstrates Rapid and Significant Pain Reduction with Elagolix

PITTSBURGH, Sept. 25 /PRNewswire/ -- invivodata inc., the industry leader in electronic patient reported outcomes (ePRO) solutions and services for global clinical research, today announced that its DiaryPRO(R) field-based ePRO system was used to capture important secondary efficacy endpoint data in Neurocrine Biosciences' (Nasdaq: NBIX) PETAL study, a Phase II clinical trial of its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with endometriosis.

Over 250 patients used invivodata's electronic diary twice daily to record the frequency and severity of endometriosis symptoms before, during, and after six months of treatment, using several different scales to measure dysmenorrhea and pelvic pain. Data captured on DiaryPRO helped Neurocrine demonstrate a clinically meaningful and statistically significant reduction in endometriosis pain from baseline among patients treated with elagolix.

"When conducting a clinical trial of this importance and magnitude, it's critical to choose a vendor that is knowledgeable about clinical development and easy to work with," said Chris O'Brien, MD, Chief Medical Officer at Neurocrine Biosciences. "invivodata's process for designing and implementing ePRO was comprehensive and straightforward, and easily fit within our clinical development timeline."

"The PETAL study represents an important step forward in Neurocrine's ongoing efforts to bring relief to patients suffering from endometriosis," said Doug Engfer, invivodata president and CEO. "We are thrilled to continue working with Neurocrine as they explore the full therapeutic potential of elagolix."

About invivodata inc.

invivodata combines behavioral science, information technology, and clinical research expertise to capture high quality clinical trial data directly from patients. invivodata's electronic Patient Reported Outcomes (ePRO) solutions, which are based on over 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata's solutions include comprehensive trial-support services that facilitate the collection of ePRO data, and web-based access to study data and operational reports that give researchers and sponsors visibility into study progress and improve trial efficiencies. invivodata's solution has been used in more than 200 trials and is the industry-leading ePRO system in delivering primary efficacy data for FDA drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters is in London, England; and its technology development center is in Scotts Valley, Calif., USA. For more information visit http://www.invivodata.com.

For more information, contact:

invivodata inc.

Christine Tobin

Corporate Communications Specialist

(412) 390-3000, ext. 3502

ctobin@invivodata.com


'/>"/>
SOURCE invivodata inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy
2. Screening for Ischemia in Asymptomatic Patients With Type 2 Diabetes: Five- Year Outcomes in the DIAD Study
3. n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure
4. Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients Day
5. Pivotal Pulmonary Arterial Hypertension Study Published in The Lancet Concludes That Bosentan (Tracleer(R)) Demonstrates Benefits in Patients With Mildly Symptomatic WHO Functional Class II Disease
6. Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
7. Bionovos Drug Candidate for Menopausal Symptoms Shows Effect on Neural Pathways Related to Temperature Regulation
8. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
9. Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
10. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
11. Concomitant Use of Nebulized Formoterol Fumarate and Tiotropium Provides Significant Improvement in Dyspnea, COPD Symptoms and Rescue Medication Use over Tiotropium Alone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... DUBLIN , Mar 23, 2017 Research ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... CAGR of around 6.9% over the next decade to reach approximately ... market estimates and forecasts for all the given segments on global ...
(Date:3/23/2017)... HICKORY, N.C. , March 23, 2017  Transportation ... accolades as an end-to-end supply chain management firm with ... of Consumer Product Solutions Rick Zaffarano was ... Star of the Supply Chain by the only publication ... the global food supply chain. "Rick has ...
(Date:3/23/2017)... 2017  The U.S. Food and Drug Administration today ... of adults and pediatric patients 12 years and older ... have not received prior chemotherapy. This is the first ... of skin cancer. "While skin cancer is ... rare form called Merkel cell cancer have not had ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 2017 , ... The law firm of Enea, Scanlan & Sirignano, LLP, ... resident Lauren C. Enea has joined the firm as an associate attorney. Ms. Enea, ... in elder law, Medicaid planning and applications, and Wills, Trusts and Estates. Samantha ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower ... upgrading their training and leads programs. , In February, 2017, Empower Brokerage introduced ... agents, Performance Partners is designed to teach how to maximize their sales efforts, ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: a dauntless and enlightened ... “End Time GPS” is the creation of published author, Wesley Gerboth, a World War ... munitions and space-vehicle projects. Now, at age ninety-one, he shares the Wisdom God bestowed ...
(Date:3/24/2017)... ... ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story ... fullest, as God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” ... passion for writing, especially about truth and human behavior. , Published by Christian Faith ...
(Date:3/23/2017)... ... ... The physicians of KSF Orthopaedic Center PA are proud to announce the ... located at 2255 E. Mossy Oaks Rd., Suite 440, Spring, Texas 77389 inside the ... living in the north Houston area (The Woodlands, Conroe, Magnolia, Kingwood, Humble) with an ...
Breaking Medicine News(10 mins):